Stephen L. Myers

TL;DR: Vertebral fracture risk reduction by teriparatide administration persists for at least 18 months after discontinuation of therapy, and post hoc analysis suggests that teripararatide treatment substantially reduced the increased risk of subsequent fracture in women who sustained a fracture during the FPT.

TL;DR: The humanised monoclonal antibody LY2495655 (LY) as discussed by the authors was used to test whether LY increases appendicular lean body mass and improves physical performance in older individuals who have had recent falls and low muscle strength and power.

TL;DR: Treatment of postmenopausal women with an antibody targeted against sclerostin resulted in substantial increases in spine and hip BMD, and further study of blosozumab as a potential anabolic therapy for osteoporosis is supported.

TL;DR: Markers of bone formation and spine BMD increased similarly with teriparatide alone and combination therapy, however, combination therapy induced a significantly smaller increase in bone resorption and total hip BMD versus baseline.

TL;DR: Treatment with LY333013 for 12 weeks was well tolerated but ineffective as an adjunct to DMARD treatment of active RA.